文献リスト

1）小林健一，清澤研道，岡上　武，編．肝硬変の成因別実態 1998．東京: 中外医学社; 1999

2）恩地森一，監修，青柳　豊，西口修平，道堯浩二郎，編．肝硬変の成因別実態 2008．東京: 中外医学社; 2009

3）高後　裕，監修，青栁　豊，橋本悦子，西口修平，他，編．我が国における非B非C肝硬変の実態調査2011．響文社: 2012. (http://www.jsh.or.jp/medical/ date /kankouhen.pdf)

4）Lin ZH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta￢analysis. Hepatology. 2011; 53: 726-36

5）Jin W, et al. Diagnostic accuracy of the aspartate aminotransferase-to￢platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis. BMC Gastroenterol. 2012; 12: 14. (http://www.biomedcentral.com/1471-230X/12/14)

6）Yilmaz Y, et al. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic liver disease. Hepat Mon. 2011; 11: 103-6

7）Adams LA, et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2011; 26: 1536-43

8）Sebastiani G, et al. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. Aliment Pharmacol Ther. 2011; 34: 1202-16

9）Zarski JP, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol. 2012; 56: 55-62

10）Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan® and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol. 2010; 53: 1013-21

11）Sebastiani G, et al. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. Aliment Pharmacol Ther. 2012; 35: 92-104

12）Boursier J, et al. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology. 2012; 55: 58-67

13）Castera L, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010; 51: 828-35

14）de Ledinghen V, et al. Feasibility of liver transient elastography with FibroScan® using a new probe for obese patients. Liver Int. 2010; 30: 1043-8

15）Friedrich-Rust M, et al. Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis. Eur Radiol. 2010; 20: 2390-6

16）Myers RP, et al. Feasibility and diagnostic performance of the FibroScan® XL probe for liver stiffness measurement in overweight and obese patients. Hepatology. 2012; 55: 199-208

17）Myers RP, et al. Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan® XL probe. J Hepatol. 2012; 56: 564-70

18）de Ledinghen V, et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®. J Hepatol. 2012; 56: 833-9

19）Friedrich-Rust M, et al. Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat. 2012; 19: e212-9

20）Piscaglia F, et al. Accuracy of VirtualTouch Acoustic Radiation Force Impulse (ARFI) imaging for the diagnosis of cirrhosis during liver ultrasonography. Ultraschall Med. 2011; 32: 167-75

21）Rizzo L, et al. Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. Am J Gastro-enterol. 2011; 106: 2112-20

22）Kircheis G, et al. Evaluation of acoustic radiation force impulse imaging for determination of liver stiffness using transient elastography as a reference. World J Gastroenterol. 2012; 18: 1077-84

23）Colombo S, et al. Head-to-head comparison of transient elastography (TE), real-time tissue elastography (RTE), and acoustic radiation force impulse (ARFI) imaging in the diagnosis of liver fibrosis. J Gastroenterol. 2012; 47: 461-9

24）Sporea I, et al. Comparative Study Concerning the Value of Acoustic Radiation Force Impulse Elastography (ARFI) in Comparison with Transient Elastography (TE) for the Assessment of Liver Fibrosis in Patients with Chronic Hepatitis B and C. Ultrasound Med Biol. 2012 Jun 12. [Epub ahead of print]

25）Shiratori Y, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepato-cellular carcinoma development and improved survival. Ann Intern Med. 2005; 142: 105-14

26）Bruno S, et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol. 2009; 104: 1147-58

27）Bruno S, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology. 2010; 51: 2069-76

28）Bourlière M, et al. Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007). Antivir Ther. 2012; 17: 101-10

29）Prati GM, et al. Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis. J Hepatol. 2012; 56: 341-7

30）Jacobson IM, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364: 2405-16

31）Zeuzem S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364: 2417-28

32）Sherman KE, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011; 365: 1014-24

33）Carrion JA, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol. 2009; 50: 719-28

34）Iacobellis A. Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis.　Clin Gastroenterol Hepatol. 2011; 9: 249-53

35）Das K, et al. Course of disease and survival after onset of decompensation in hepatitis B virus-related cirrhosis. Liver Int. 2010; 30: 1033-42

36）Chang TT, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010; 52: 886-93

37）European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57: 167-85

38）Shim JH, et al. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2010; 52: 176-82

39）Bass NM, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010; 362: 1071-81

40）Sanyal A, et al. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2011; 34: 853-61

41）Bajaj JS, et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology. 2011; 140: 478-87

42）Eltawil KM, et al. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol. 2012; 18: 767-77

43）Serste T, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology. 2010; 52: 1017-22

44）Serste T, et al. Beta-blockers cause paracen-tesis￢induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol. 2011; 55: 794-9

45）Wong F, Beta-blockers in cirrhosis: friend and foe? Hepatology. 2010; 52: 811-3

46）Angeli P.β-blockers and refractory ascites in cirrhosis: the message of a team of true scientists. J Hepatol. 2011; 55: 743-44

47）Singh V, et al. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. J Hepatol. 2012; 56: 348-54

48）Appenrodt B, et al. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology. 2010; 51: 1327-33

49）Bruns T, et al. NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. Liver Int. 2012; 32: 223-30

50）Nischalke HD, et al. Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol. 2011; 55: 1010-6

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp